Investor Overview

Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News

Recent News

Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation  -  9/14/2020
Innovative technology platform for cell-free DNA testing in oncology and organ transplantation uniquely positions Natera to help improve outcomes for the most vulnerable transplant patients SAN CARLOS, Calif. , Sept. 14, 2020 /PRNewswire/ --  Natera, Inc. More »
Natera's Signatera™ MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer  -  9/11/2020
SAN CARLOS, Calif. , Sept. 11, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative Contractor (MAC) for Northern California , has finalized a final local coverage article (LCA) to provide More »
Natera Announces Pricing of Follow-On Offering  -  9/11/2020
SAN CARLOS, Calif. , Sept. 10, 2020 /PRNewswire/ --  Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 4,166,666 shares of its common stock at a price to the public of $60.00 per share. More »
Natera to Present at the Morgan Stanley 18th Annual Global Healthcare Conference  -  9/10/2020
SAN CARLOS, Calif. , Sept. 10, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Morgan Stanley 18th Annual Global Healthcare Conference taking place virtually on Monday, Sept. More »
Natera Launches Proposed Follow-On Offering  -  9/9/2020
SAN CARLOS, Calif. , Sept. 9, 2020 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day More »
Event

Upcoming Events

More events are coming soon.
Events

Past events

Date
Title

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.